Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.58 |
| ▸ | PGR | P06401 | 7/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.58 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291862 | 0.92 | NR3C1 (0.56) | NR3C1PGRNR3C2ARPDK1 | |
| SCHEMBL451495 | 0.89 | PDK1 (0.55) | NR3C1PGRNR3C2ARPDK1 | |
| SCHEMBL290544 | 0.85 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL6686666 | 0.85 | NR3C1 (0.67) | NR3C1PGRNR3C2ARPDK1 | |
| SCHEMBL1931881 | 0.84 | NR3C1 (0.55) | NR3C1PGRNR3C2PDK1PDK2 | |
| SCHEMBL292969 | 0.84 | NR3C1 (0.65) | NR3C1PGRNR3C2AR | |
| SCHEMBL292361 | 0.83 | NR3C1 (0.61) | NR3C1PGRNR3C2AR | |
| SCHEMBL291720 | 0.82 | NR3C1 (0.64) | NR3C1PGRNR3C2AR | |
| SCHEMBL291836 | 0.82 | NR3C1 (0.64) | NR3C1PGRNR3C2AR | |
| SCHEMBL292680 | 0.81 | NR3C1 (0.62) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| EP-2049112-B1 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | 1261229 B.C. LTD. (CA) | 2011-11-17 | — | — | US | disclosed |
| EP-2051710-B1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2364707-A2 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110104159-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH+LOMB OPS B.V. (NL) | 2011-05-05 | — | — | US | disclosed |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-05-05 | — | — | US | disclosed |
| EP-2061444-B1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB (US) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | PTGIR, MC2R, NR3C1 | NR3C1 3/4885PGR 220/4885NR3C2 18/4885 |
| US-20110104159-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885PGR 123/4885NR3C2 87/4885 |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885PGR 123/4885NR3C2 87/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885PGR 272/4885NR3C2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.